Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Fate Therapeutics, Inc. (NASDAQ: FATE).

Full DD Report for FATE

You must become a subscriber to view this report.


Recent News from (NASDAQ: FATE)

Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies
SAN DIEGO, May 16, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today the Company has gained access to additional inte...
Source: GlobeNewswire
Date: May, 16 2018 08:00
Fate Therapeutics' (FATE) CEO Scott Wolchko on Q1 2018 Results - Earnings Call Transcript
Fate Therapeutics, Inc. (FATE) Q1 2018 Results Earnings Conference Call May 10, 2018, 05:00 PM ET Executives Scott Wolchko - President and CEO Chris Storgard - Chief Medical Officer Dan Shoemaker - Chief Scientific Officer Analysts Edward Tenthoff - Piper Jaffray David Ni...
Source: SeekingAlpha
Date: May, 10 2018 22:11
Fate Therapeutics misses by $0.05, misses on revenue
Fate Therapeutics (NASDAQ: FATE ): Q1 EPS of -$0.27 misses by $0.05 . More news on: Fate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 10 2018 16:07
Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress
No Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in Advanced Solid and Liquid Tumors IND for Off-the-Shelf NK Cell Product FT500 Remains on Track for 2Q18 ...
Source: GlobeNewswire
Date: May, 10 2018 16:01
Notable earnings after Thursday's close
AL , AMBR , ARCB , ASYS , AVID , CASA ,  CSLT , DCO , DOX , FATE , FLS , GLOB , HALO , HUBS , IMMR , JAG , KTOS , NDLS , NKTR , NVDA , NWSA , OMER , PEGA , PFLT , PPC , PSDO , RBA , RDFN , SGYP , SSRM , SYMC , TIVO , TLND , TTD , UEPS , UNIT , VRAY ...
Source: SeekingAlpha
Date: May, 09 2018 10:35
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results
SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and...
Source: GlobeNewswire
Date: May, 03 2018 16:01
Fate Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Chief Scientific Officer, wi...
Source: GlobeNewswire
Date: May, 02 2018 08:00
Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program
Off-the-Shelf CAR T-cell Product Candidate Designed to Target CD19-positive Tumor Cells and to Overcome Antigen Escape Manufacture from Master iPSC Line Enables Mass Production and Broad Accessibility without Patient Restriction AACR Press Program to Begin Today at 8:30 a.m. Centr...
Source: GlobeNewswire
Date: April, 16 2018 09:30
Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned
Biotech Pulse When the market experiences rain, biotechs experience a thunderstorm. That's how volatility relates to biotechnology - one of the most promising and nerve-wracking industries in the stock market. As the market succumbed last week to the drumbeat of a tariff war, volatility sp...
Source: SeekingAlpha
Date: April, 13 2018 09:17
Wired News - Fate Therapeutics Presented Positive Clinical Data of FATE-NK100's APOLLO Phase-1 Study in Recurrent Ovarian Cancer at the Innate Killer Summit 2018
Stock Monitor: Aeterna Zentaris Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 3, 2018 / Active-Investors.com has just released a free research report on Fate Therapeutics, Inc. (NASDAQ: FATE ). If you want access to this report all you need to do is sign up now by clicking ...
Source: ACCESSWIRE IA
Date: April, 03 2018 07:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-2011.2010.8511.2610.78233,758
2018-08-1711.0711.1911.236510.76137,815
2018-08-1610.9411.0111.14510.69146,758
2018-08-1511.3110.8611.3910.70207,071
2018-08-1411.1411.2111.4611.015207,952

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2035,26558,44860.3357Short
2018-08-1730,95037,38382.7916Short
2018-08-1625,83434,29475.3310Short
2018-08-1541,25757,27672.0319Short
2018-08-1437,78965,39657.7849Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FATE.


About Fate Therapeutics, Inc. (NASDAQ: FATE)

Logo for Fate Therapeutics, Inc. (NASDAQ: FATE)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: FATE)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: May, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: March, 19 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 16 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: March, 16 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 05 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 05 2018

       

       


      Daily Technical Chart for (NASDAQ: FATE)

      Daily Technical Chart for (NASDAQ: FATE)


      Stay tuned for daily updates and more on (NASDAQ: FATE)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: FATE)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FATE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of FATE and does not buy, sell, or trade any shares of FATE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/